Letrozol Alter

Letrozole, the active ingredient in Letrozol Alter, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed in the endocrine therapy of hormone receptor‑positive breast cancer in postmenopausal women, reducing estrogen production that can fuel tumor growth.

GNH USA supplies Letrozol Alter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for oncology treatments across global markets today.

Letrozole is an aromatase inhibitor used in the management of estrogen‑dependent breast cancer.

Hormone receptor‑positive early breast cancer: reduces risk of recurrence. Hormone receptor‑positive advanced/metastatic breast cancer: slows disease progression. Adjuvant endocrine therapy in postmenopausal women: improves disease‑free survival.

Common Side Effects: - Hot flashes: sudden feeling of warmth, often with sweating. - Joint and muscle pain: aching in joints or muscles. - Fatigue: persistent tiredness not relieved by rest. - Nausea: mild to moderate upset stomach. - Headache: intermittent or persistent head pain. - Dizziness: sensation of light‑headedness or imbalance.

Serious or Rare Side Effects: - Severe liver injury: jaundice, elevated liver enzymes. - Bone fracture: increased risk due to reduced bone density. - Pulmonary embolism: sudden shortness of breath, chest pain. - Myocardial infarction: heart attack symptoms. - Severe allergic reaction: rash, swelling, difficulty breathing. - Elevated cholesterol: significant rise in blood lipid levels.

Before initiating therapy, consider the following precautions: - Pregnancy: contraindicated (Category X) – do not use in pregnant women. - Breastfeeding: not recommended – avoid during lactation. - Bone health: monitor bone mineral density regularly. - Liver function: assess hepatic enzymes before and during treatment. - Cardiovascular disease: use cautiously in patients with severe heart conditions. - Store at ambient temperature below 25°C: keep in original packaging, protect from moisture.

Letrozole may interact with several medicines.

Major Interactions (Avoid): - Estrogen replacement therapy: antagonizes letrozole’s effect. - Other aromatase inhibitors: additive estrogen suppression may increase toxicity. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise letrozole plasma levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce efficacy. - Warfarin: monitor INR for altered anticoagulation. - Selective serotonin reuptake inhibitors: possible effect on metabolism. - Antacids containing aluminum or magnesium: may affect absorption.